The first participant has been dosed in a proof-of-concept, open-label Phase 2a clinical trial testing Consynance Therapeutics’ experimental oral therapy CSTI-500 in adolescents and adults with Prader-Willi syndrome (PWS). Supported in part by a venture philanthropy investment from the Foundation for Prader-Willi Research (FPWR), the Phase 2a study…
Discussion
Treatment with setmelanotide helped reduce uncontrollable hunger, known as hyperphagia, and also eased anxiety in children and adults with obesity due to Prader-Willi syndrome (PWS). The Rhythm Pharmaceuticals‘ experimental injection therapy was also shown to reduce body fat and preserve lean mass in individuals with PWS. That’s according…
Discussion
Most infants with Prader-Willi syndrome (PWS) experience sleep-disordered breathing and obstructive sleep apnea before ever starting growth hormone therapy, a small Belgian study shows. The findings challenge previous suggestions that growth hormone therapy, a standard treatment for PWS, is what primarily drives the risk of obstructive sleep apnea (OSA),…
Prader-Will syndrome is a rare and complex genetic condition that results in a variety of physical and mental symptoms. Learn more about the disease here.
Prader-Willi is caused by genetic changes in a particular area of chromosome 15. Learn more about what causes the disease here.
Symptoms of Prader-Willi range from physical impairments to cognitive and behavioral issues. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
